SCHEMBL2839734

SCHEMBL2839734

COc1cc(-c2cncc(F)c2)ccc1C(O)C(NC(=O)OC(C)(C)C)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 3/20 0.36
CYP3A4 P08684 4/20 0.35
CYP2D6 P10635 3/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
SLC6A3 Q01959 3/20 0.35
KCNH2 Q12809 1/20 0.35
DYRK1A Q13627 1/20 0.35
AAK1 Q2M2I8 5/20 0.34
ROCK2 O75116 2/20 0.33
ROCK1 Q13464 2/20 0.33
SCN9A Q15858 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
AKT1 P31749 1/20 0.33
S1PR1 P21453 1/20 0.33
PDGFRB P09619 1/20 0.32
PDGFRA P16234 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834950 0.88 S1PR3 (0.40) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL2843147 0.86 AKR1C3 (0.41) S1PR3KCNH2DYRK1AAAK1ROCK2
SCHEMBL2839096 0.82 S1PR3 (0.42) S1PR3CYP3A4DYRK1AAAK1ROCK2
SCHEMBL2838698 0.81 CYP3A4 (0.36) S1PR3CYP3A4DYRK1AAAK1
SCHEMBL2834200 0.80 EIF2S1 (0.38) S1PR3CYP3A4DYRK1AAAK1ROCK2
SCHEMBL7803621 0.79 CYP3A4 (0.39) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2841558 0.79 S1PR3 (0.38) S1PR3CYP3A4DYRK1AAAK1
SCHEMBL2833981 0.76 CYP3A4 (0.40) S1PR3CYP3A4DYRK1AAAK1AKR1C3
SCHEMBL2837542 0.75 S1PR3 (0.43) S1PR3CYP3A4DYRK1AAAK1AKT1
SCHEMBL2836835 0.75 S1PR3 (0.41) S1PR3KCNH2ROCK2ROCK1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CYP3A4 1043/4885CYP2D6 767/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CYP3A4 1043/4885CYP2D6 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.